Marc J. Braunstein, MD, PhD

Explore 2026 CLL frontline choices, from all-oral acalabrutinib–venetoclax to MRD-guided care, plus pipeline advances and Richter’s strategies.

Experts explore the evolving landscape of chronic lymphocytic leukemia treatment, highlighting targeted therapies, MRD strategies, and future innovations.

Marc J. Braunstein, MD, PhD, discusses chimeric antigen receptor T-cell therapies, Bruton’s kinase inhibitors, and brentuximab vedotin that were highlighted at the 2020 Chemotherapy Foundation Symposium.

Marc J. Braunstein, MD, PhD, discusses the greatest challenge that still exists in the treatment paradigm of multiple myeloma.